...
首页> 外文期刊>Molecular pharmacology. >Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.
【24h】

Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.

机译:曲格列酮的胆汁淤积潜力可能是曲格列酮诱导的肝毒性的可能因素:大鼠小管胆盐输出泵(Bsep)的体内和体外相互作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Troglitazone is a thiazolidinedione insulin sensitizer drug for the treatment of type 2 non-insulin-dependent diabetes mellitus (NIDDM). Based on an increasing number of reports on troglitazone-associated liver toxicity, the cholestatic potential of troglitazone has been investigated. Rapid and dose-dependent increases in the plasma bile acid concentrations were observed in rats after a single intravenous administration of troglitazone. A radiolabeled taurocholic acid tracer accumulated in liver tissue, indicating an interference with the hepatobiliary export of bile acids. In isolated canalicular rat liver plasma membrane preparations, troglitazone competitively inhibited the ATP-dependent taurocholate transport (apparent K(i) value, 1.3 microM), mediated by the canalicular bile salt export pump (Bsep). Troglitazone sulfate, the main troglitazone metabolite eliminated into bile, also showed competitive Bsep inhibition with an apparent K(i) value of 0.23 microM. A comparable inhibition was observed for both compounds in canalicular plasma membrane vesicles prepared from Mrp2-deficient (TR(-)) rats, suggesting a direct (cis-) inhibition of Bsep by troglitazone and troglitazone sulfate. A high accumulation potential was observed for troglitazone sulfate in rat liver tissue, indicating that the hepatobiliary export of this conjugated metabolite might represent a rate-limiting step in the overall elimination process of troglitazone. This accumulation in combination with the high Bsep inhibition potential suggested that mainly troglitazone sulfate was responsible for the interaction with the hepatobiliary export of bile acids at the level of the canalicular Bsep in rats. Such an interaction might lead to a troglitazone-induced intrahepatic cholestasis in humans as well, contributing to the formation of a troglitazone-induced liver toxicity.
机译:曲格列酮是噻唑烷二酮胰岛素增敏剂,用于治疗2型非胰岛素依赖型糖尿病(NIDDM)。基于与曲格列酮相关的肝毒性的报告越来越多,已经研究了曲格列酮的胆汁淤积潜力。在单次静脉注射曲格列酮后,在大鼠中观察到血浆胆汁酸浓度快速且剂量依赖性增加。放射性标记的牛磺胆酸示踪剂在肝组织中积累,表明干扰了胆汁酸的肝胆输出。在分离的小管大鼠肝质膜制剂中,曲格列酮竞争性抑制由小管胆汁盐输出泵(Bsep)介导的ATP依赖的牛磺胆酸盐转运(表观K(i)值为1.3 microM)。硫酸曲格列酮硫酸盐,主要的曲格列酮代谢产物消除为胆汁,也显示出竞争性的Bsep抑制作用,表观K(i)值为0.23 microM。在缺少Mrp2的(TR(-))大鼠制备的小管质膜囊泡中,两种化合物均具有类似的抑制作用,这表明曲格列酮和硫酸曲格列酮对Bsep具有直接(顺式)抑制作用。观察到曲格列酮硫酸盐在大鼠肝组织中具有很高的积累潜力,这表明这种共轭代谢产物的肝胆输出可能是曲格列酮整个清除过程中的限速步骤。这种积累与高Bsep抑制潜能相结合,表明在大鼠小管Bsep水平上,硫酸曲格列酮主要与胆汁酸的肝胆输出相互作用。这种相互作用也可能导致曲格列酮诱导的人肝内胆汁淤积,从而导致曲格列酮诱导的肝毒性的形成。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号